glp 1 can you stop GLP-1 Medications Without Weight Gain? What happens when you stop

4 Challenges and future directions 4.1 Safety considerations The safety profile of dual or triple receptor agonists targeting GLP-1, GIP, and GCG receptors in the treatment of MASLD and related metabolic disorders warrants careful evaluation

Tolerance to these adverse events can develop, but patients should contact their provider if intolerable

These include signs of pancreatitis (severe, persistent abdominal pain radiating to the back, often accompanied by vomiting) and gallbladder problems (right upper abdominal pain, fever, jaundice)

DSIP discussions online often come from research summaries, wellness clinics, or peptide communities, not from an official product label meant for routine patient use